Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a brain zap help when PTSD talk therapy falls short?

NCT ID NCT07693088

Symptom relief Sponsor: Aarhus University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether adding a type of brain stimulation called intermittent theta-burst stimulation (iTBS) can help adults with post-traumatic stress disorder (PTSD) who do not improve enough with standard eye movement desensitization and reprocessing (EMDR) therapy alone. Participants first receive weekly EMDR sessions. Those who still have significant symptoms after seven sessions then receive iTBS (targeted to a brain region involved in emotion regulation) for four weeks while continuing EMDR. The main goals are to see if this combined approach is feasible, safe, and tolerable, and to gather early data on symptom changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intermittent theta-burst stimulation (iTBS) device
What this could lead to
If this approach is feasible and shows promise, it could point toward a way to help people with PTSD who do not get enough relief from standard therapy alone.
What could go wrong
This is a very small pilot study with only 15 people, so results may not apply widely. The added stimulation may not provide extra benefit and could cause side effects like discomfort or headache.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-70 years * ICD-10 criteria for PTSD (F43.1) * A minimum total score of 4 (moderately ill) on the Clinical Global Impression-Severity (CGI-S) * Likely to be able to complete trial participation (16 weeks) without modifications to psychopharmacological treatment, as per the referring doctor's or psychologist's assessment * Participants must be able and willing to abstain from alcohol consumption during the iTBS treatment period, as required by the TMS Safety Checklist. Exclusion Criteria: * Organic mental disorders (F0) * Currently fulfills the criteria of Active psychoactive substance use or dependence (F1) * Schizophrenia, schizotypal and delusional disorders (F2), manic episode (F30), or bipolar affective disorder (F31); iv) Mental retardation (estimated IQ \<70, as per the referring doctor's or psychologist's assessment) * Active suicidality * Any ongoing involuntary/coercive measures * Any contraindications listed on the TMS Safety Checklist

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTSD, post traumatic stress disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

combat disorder post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PTSD, post traumatic stress disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus N, Denmark

  • Regional Psychiatry Central Jutland

    Viborg, Denmark

  • Regional Psychiatry Horsens

    Horsens, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.